TY - JOUR

T1 - Бициклол в лечении пациентов с хроническими диффузными заболеваниями печени

AU - Maevskaya, Marina V.

AU - Lunkov, Valeriy D.

AU - Geyvandova, Natalia I.

AU - Palgova, Lyudmila K.

AU - Pirogova, Irina Yu

AU - Prashnova, Mariya K.

AU - Marchenko, Natalia V.

AU - Zinovieva, Evgeniya N.

AU - Ilchishina, Tatiana A.

AU - Ivashkin, Vladimir T.

AU - Koroy, Pavel V.

N1 - Publisher Copyright: © 2020, Remedium Group Ltd. All rights reserved.

PY - 2020

Y1 - 2020

N2 - Introduction. The increase in serum transaminases (ALT and AST) and the persistence of their high values is associated with mor-bidity and mortality from liver diseases. Bicyclol has anti-inflammatory and antioxidant effects, which formed the basis for this study. Materials and methods. The study enrolled 51 patients (MELD < 19); hepatitis stage – 84.4%, cirrhosis – 15.6%. Treatment: Bicyclol 75 mg/day for 12 weeks. Criteria of efficacy: dynamics of ALT, AST, CRP; general well-being (D-FIS scale). Results. After 4 weeks of treatment the share of patients with ALT normalization was 50,9% (p < 0,001); with AST normalization – 62.7% (p < 0.001); after 12 weeks-79,5% and 89,7% respectively (p < 0,001). CRP decreased statistically significantly after 2 and 4 weeks from the beginning of treatment. The D-FIS questionnaire was filled in by 36 patients at the beginning of the study, in 4 weeks-by 35 patients, in 12 weeks – by 32 patients. Median D-FIS decreased from 12 (8.2; 32.2) to 8 (5; 29) points (p < 0,001) after 4 weeks of treatment, after 12 weeks – to 6.5 (3; 28.5) points (p < 0.001). The CRP was positively correlated with the D-FIS value. Fibrosis (“Fibromax”, “Fibroscan”) was studied in 10 additional patients, the dose of Bicyclol was 150/75 mg/day during 6 months, the result was statistically significant (p < 0.001). Conclusion. Application of Bicyclol leads to reduction of fatigue, local and systemic inflammation, fibrosis in chronic diffuse liver diseases regardless of etiology.

AB - Introduction. The increase in serum transaminases (ALT and AST) and the persistence of their high values is associated with mor-bidity and mortality from liver diseases. Bicyclol has anti-inflammatory and antioxidant effects, which formed the basis for this study. Materials and methods. The study enrolled 51 patients (MELD < 19); hepatitis stage – 84.4%, cirrhosis – 15.6%. Treatment: Bicyclol 75 mg/day for 12 weeks. Criteria of efficacy: dynamics of ALT, AST, CRP; general well-being (D-FIS scale). Results. After 4 weeks of treatment the share of patients with ALT normalization was 50,9% (p < 0,001); with AST normalization – 62.7% (p < 0.001); after 12 weeks-79,5% and 89,7% respectively (p < 0,001). CRP decreased statistically significantly after 2 and 4 weeks from the beginning of treatment. The D-FIS questionnaire was filled in by 36 patients at the beginning of the study, in 4 weeks-by 35 patients, in 12 weeks – by 32 patients. Median D-FIS decreased from 12 (8.2; 32.2) to 8 (5; 29) points (p < 0,001) after 4 weeks of treatment, after 12 weeks – to 6.5 (3; 28.5) points (p < 0.001). The CRP was positively correlated with the D-FIS value. Fibrosis (“Fibromax”, “Fibroscan”) was studied in 10 additional patients, the dose of Bicyclol was 150/75 mg/day during 6 months, the result was statistically significant (p < 0.001). Conclusion. Application of Bicyclol leads to reduction of fatigue, local and systemic inflammation, fibrosis in chronic diffuse liver diseases regardless of etiology.

KW - Biciclol

KW - Fibrosis

KW - Serum transaminases

KW - Systemic and local inflammation

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85100909263&partnerID=8YFLogxK

U2 - 10.21518/2079-701X-2020-15-78-89

DO - 10.21518/2079-701X-2020-15-78-89

M3 - статья

AN - SCOPUS:85100909263

VL - 2020

SP - 78

EP - 89

JO - МЕДИЦИНСКИЙ СОВЕТ

JF - МЕДИЦИНСКИЙ СОВЕТ

SN - 2079-7028

IS - 15

ER -